<DOC>
	<DOCNO>NCT00291837</DOCNO>
	<brief_summary>The purpose sudy determine response rate CT-2106 patient advanced ovarian cancer fail one prior platinum taxane base regimen .</brief_summary>
	<brief_title>CT-2106 Second Line Treatment Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patients advance ovarian carcinoma , fail one prior platinum taxane contain regimen Only one prior chemotherapy contain either cisplatin carboplatin plus taxanes administer concomitantly At least one measurable lesion accord RECIST ECOG performance status 0 1 least 18 year old Adequate haematological function Adequate renal hepatic function Normal coagulation parameter Platinumsensitive patient ( Group 2 ) respond ( CR PR ) 1st line therapy subsequently progress relapsed treatmentfree interval &gt; 12 month Pregnant lactating patient Prior treatment camptothecins Presence history CNS metastasis carcinomatous leptomeningitis ; Current active infection per investigator assessment ; Unresolved bowel obstruction subobstruction , uncontrolled Crohn 's disease ulcerative colitis ; Current history chronic diarrhea &gt; = grade 1 ( CTCAE version 3 ) ; Surgery radiotherapy ≤ 4 week first study treatment . In case cytoreductive surgery progression disease , ≤ 2 week 1st study treatment allow ; Other uncontrolled , serious illness medical condition , determine investigator ; Concomitant ( within 4 week inclusion ) administration experimental drug investigation ; Concurrent treatment anticancer therapy ; Known HIV positivity AIDSrelated illness ; Patients regularly follow psychological , social , familial geographic reason .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>ovarian</keyword>
	<keyword>CT-2106</keyword>
</DOC>